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Abstract
Background: Glucocorticoids (GCs) control expression of a large number of genes via binding to the GC receptor (GR). 
Transcription may be regulated either by binding of the GR dimer to DNA regulatory elements or by protein-protein 
interactions of GR monomers with other transcription factors. Although the type of regulation for a number of 
individual target genes is known, the relative contribution of both mechanisms to the regulation of the entire 
transcriptional program remains elusive. To study the importance of GR dimerization in the regulation of gene 
expression, we performed gene expression profiling of livers of prednisolone-treated wild type (WT) and mice that 
have lost the ability to form GR dimers (GRdim).
Results: The GR target genes identified in WT mice were predominantly related to glucose metabolism, the cell cycle, 
apoptosis and inflammation. In GRdim mice, the level of prednisolone-induced gene expression was significantly 
reduced compared to WT, but not completely absent. Interestingly, for a set of genes, involved in cell cycle and 
apoptosis processes and strongly related to Foxo3a and p53, induction by prednisolone was completely abolished in 
GRdim mice. In contrast, glucose metabolism-related genes were still modestly upregulated in GRdim mice upon 
prednisolone treatment. Finally, we identified several novel GC-inducible genes from which Fam107a, a putative 
histone acetyltransferase complex interacting protein, was most strongly dependent on GR dimerization.
Conclusions: This study on prednisolone-induced effects in livers of WT and GRdim mice identified a number of 
interesting candidate genes and pathways regulated by GR dimers and sheds new light onto the complex 
transcriptional regulation of liver function by GCs.
Background
Naturally occurring glucocorticoids (GCs), such as corti-
sol, play an important role in the regulation of cardiovas-
cular, metabolic and immunological processes. GCs are
potent suppressors of inflammatory indices and are
widely used to treat chronic inflammatory diseases such
as rheumatoid arthritis and asthma [1-3]. However,
chronic use of GCs induces side effects, such as diabetes
mellitus, fat redistribution, osteoporosis, muscle atrophy,
glaucoma and skin thinning [4].
One of the aspects influencing the balance between the
desired anti-inflammatory effects and the side effects of
GCs is the activation and repression of gene expression.
After binding of GCs to the cytosolic GC receptor (GR),
the receptor-ligand complex translocates to the nucleus
where it alters gene expression. Ligand-bound GR can
influence the expression of target genes, either by binding
as a dimer to palindromic GC response elements (GRE)
or tethering to other DNA-bound transcription factors
[5,6].
It is generally assumed that the anti-inflammatory
actions of GCs are mainly driven by transrepression, in
which ligand-bound GR binds to the pro-inflammatory
transcription factors NF-κB (Nuclear factor kappa-light-
chain-enhancer of activated B cells), AP-1 (Activator pro-
tein 1), IRF-3 (Interferon regulatory factor 3) or other fac-
tors, forming an inactive transcription machinery
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complex, which prevents expression of pro-inflammatory
genes [7-16]. However, recent studies demonstrated that
under some inflammatory conditions DNA dimer-depen-
dent gene expression could also contribute to the anti-
inflammatory activities of the GR [17]. The occurrence of
side effects has been linked mainly to transactivation of
gene transcription. The well-documented example of
GC-induced upregulation of Pck1 (Phosphoenolpyruvate
carboxykinase 1; also known as Pepck) and G6pc (Glu-
cose-6-phosphatase), two genes encoding key enzymes
that control gluconeogenesis, is one example linking
transactivation to metabolic side effects [18-20].
One of the mechanisms by which GR activates gene
transcription is by binding as a homodimer to a GRE in
the promoter region of a target gene. GR dimerization
involves the D loop located in the DNA-binding domain
of the GR, in which several amino acids interact to facili-
tate receptor dimer formation. It was shown that an
A458T point mutation, introduced in the D loop of the
GR (GRdim), impairs homodimerization and ablates DNA
binding [21]. Mice carrying this GRdim  mutation are
almost as effective as wild type (WT) mice in repressing
AP-1 and NF-κB-modulated gene transcription, whereas
GR-mediated  Tat  (Tyrosine aminotransferase) mRNA
induction is largely abolished [21,22].
The mechanism of dimer-dependent transactivation by
the GR has been studied in detail for a limited number of
GR target genes, including Fkbp5 (FK506 binding protein
5), Tat, Pck1 and Dusp1 (Dual specificity phosphatase 1)
[23-26], and tethering-facilitated transrepression of
Mmp1/Mmp13  (Matrix metallopeptidase 1/13),  IL-8
(Interleukin 8) and others [27-29]. In order to perform a
comprehensive study of the genes and cellular processes
that are affected by GC-treatment and influenced by GR
dimerization, we have performed genome wide gene
expression profiling in liver of prednisolone-treated WT
and GRdim mice.
We found that prednisolone predominantly influenced
expression of genes involved in glucose metabolism,
inflammation, the cell cycle and apoptosis. In general,
activation of transcription, including transactivation of
known GR marker genes such as Fkbp5 and Tat, was sig-
nificantly reduced, but not totally absent in the GRdim
mutant. However, a total absence of transcriptional trans-
activation upon GC-treatment was observed in GRdim
mice for a subset of genes, all related to regulation of the
cell cycle. In contrast, a small subset of genes was found
exclusively regulated by GCs in GRdim mice. Furthermore,
we identified Fam107a (Family with sequence similarity
107, member a; also known as Tu3a and Drr1) as a novel
G C - i n d u c i b l e  g e n e  t h a t  c o m p l e t e l y  r e l i e s  o n  G R
dimerization for transactivation.
Results
Clustering of individual samples
In order to chart the gene expression profile induced by
prednisolone in WT and GRdim mice, 6 mice per group
were treated with prednisolone or vehicle. A principal
component analysis (PCA) on the normalized intensity
data showed that the samples clustered into four distinct
groups (Figure 1). The largest separation, represented by
PC1, was observed between samples derived from male
versus female mice. The genes with the highest gender
specificity belong to the family of cytochrome P450 pro-
teins, such as Cyp3a41, Cyp3a44 and Cyp4a12, which are
known for their gender-specific expression [30,31]. In
addition to the gender-based separation, a clear separa-
tion was observed between prednisolone-treated and
vehicle-treated WT mice, whereas prednisolone-treated
GRdim  mice clustered closely together with vehicle-
treated GRdim and WT mice (PC2). These results indicate
that there is a significant prednisolone effect in WT mice,
which is strongly reduced in prednisolone-treated GRdim
mice. Genes with high loading scores on PC2 include Tat
and Fkbp5, which are known GR-regulated genes in liver
[32,33] (Figure 2).
These results show that the transcriptional program
that is induced by prednisolone in WT mice is strongly
reduced in mice carrying the GRdim mutation. This sup-
Figure 1 Principal component analysis on gene expression inten-
sity data. A principal component analysis (PCA) was performed on 
normalized gene expression intensity data from 12 wild type (WT) mice 
(vehicle and prednisolone treatment) and 12 GRdim mice (vehicle and 
prednisolone treatment). Bullets: WT mice; Triangles: GRdim mice. White 
symbols: vehicle-treated mice; Black symbols: prednisolone-treated 
mice. The largest separation was seen between samples derived from 
male versus female mice (PC1).Frijters et al. BMC Genomics 2010, 11:359
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ports the hypothesis that the loss of GR dimerization
leads to a reduction in transcriptional transactivation by
the GR and underscores the importance of GR dimeriza-
tion in induction of gene expression. The effect of predni-
solone on up and downregulated genes and pathways will
be discussed in more detail below.
Prednisolone-induced changes in gene expression
To quantify the differences that were seen in the multi-
variate analysis, differentially expressed probe sets were
identified for several treatment comparisons (e.g. predni-
solone versus vehicle-treated WT mice and prednisolone
vs. vehicle-treated GRdim mice). Probe sets were marked
as differentially regulated when the p-value, corrected for
multiple testing, was below the 0.01 cutoff value.
Prednisolone treatment resulted in a significant differ-
ential regulation of 518 probe sets in WT mice (347
upregulated and 171 downregulated; Additional file 1),
whereas in prednisolone-treated GRdim  mice only 34
probe sets were differentially regulated (29 upregulated
and 5 downregulated; Additional file 2). Notably, no dif-
ferentially regulated probe sets were found in the com-
parison between vehicle-treated GRdim  and vehicle-
treated WT mice, suggesting that the GRdim mutation
itself does not cause differential gene regulation and that
the effects between WT and GRdim mice only become
apparent after treatment with prednisolone.
The observation that only 34 probe sets are differen-
tially regulated in GRdim mice upon prednisolone treat-
ment, suggests that there is almost no regulation of gene
expression by prednisolone in GRdim mice. However, a
large number of the probe sets that are differentially reg-
ulated in WT mice showed the same direction of regula-
tion by prednisolone in GRdim mice, but did not meet the
cutoff value of 0.01 for the p-value. This indicates that
induction of gene expression by prednisolone in GRdim
mice is strongly reduced but not completely absent (see
below).
Taken together these data are in line with the hypothe-
sis that transactivation of gene expression through the
GR is significantly reduced in mice carrying the GRdim
mutation.
Biological processes targeted by prednisolone in WT mice
In order to identify cellular processes on which predniso-
lone has a prominent effect, a gene set enrichment analy-
sis was conducted using the 518 probe sets that were
differentially regulated in WT mice by prednisolone. For
this analysis we used CoPub, a text mining tool that cal-
culates which biological processes are significantly asso-
ciated to a set of genes [34]. It appeared that the
differentially regulated genes are predominantly involved
in three major processes: (glucose) metabolism, cell
cycle/apoptosis and immune/inflammatory response
(Table 1).
In order to gain insight into the relationships between
genes and cellular processes a network representation
was created, in which differentially regulated genes are
plotted together with enriched keywords. In this repre-
sentation, cellular processes that are affected by predni-
solone can be appreciated as separate areas in the
network, such as cell cycle and apoptosis, acute-phase
response, and metabolism-related processes such as
amino acid metabolism, gluconeogenesis and lipid
metabolism. The most influential genes appear as highly
connected hubs (Figure 3). Important factors that seem
to connect the gluconeogenesis and the cell cycle and
apoptosis subnetworks are the transcription factors
Foxo1 and Foxo3a (Forkhead box O1 and Forkhead box
O3a; see below).
Strong effects of prednisolone treatment on gluconeo-
genesis, the cell cycle and apoptosis are in line with the
anticipated effect of the GR in the liver. The fact that
many inflammation and acute phase response-related
genes, such as IL6r (Interleukin 6 receptor) and Cxcl12
(Chemokine (C-X-C motif) ligand 12) were regulated (Fig-
ure 3) is interesting, given that we analyzed livers from
healthy mice, not challenged with inflammatory stimuli.
The direction and magnitude of prednisolone-induced
differential regulation of genes involved in gluconeogene-
sis and the cell cycle was studied in more detail to get
more insight into these prednisolone-affected processes.
Figure 2 Intensity profiles of Tat and Fkbp5 in vehicle and predni-
solone-treated wild type versus GRdim mice. The expression intensi-
ties of Tat (Tyrosine aminotransferase) and Fkbp5 (FK506 binding protein 
5) in vehicle-treated (white bars) and prednisolone-treated (grey bars) 
wild type (WT) and GRdim mice are plotted. Symbols: Bullets: male mice; 
Triangles: female mice. Both Tat and Fkbp5 are known GR marker genes 
and show strong differential regulation in prednisolone-treated WT 
mice.Frijters et al. BMC Genomics 2010, 11:359
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Gluconeogenesis
Table 2 shows the prednisolone-regulated genes in WT
mice identified by CoPub as being associated with gluco-
neogenesis. Among the upregulated genes are Pck1,
encoding the rate limiting enzyme in gluconeogenesis
[35], Ppargc1a (Peroxisome proliferative activated recep-
tor, gamma, coactivator 1 alpha), a transcriptional coacti-
vator that coordinates the expression of genes involved in
gluconeogensis and ketogenesis [36], and Sds  (Serine
dehydratase) and Aass (Aminoadipate-semialdehyde syn-
thase), two genes encoding enzymes involved in amino
acid catabolism and amino acid utilization for gluconeo-
genesis [37,38].
The set of downregulated genes includes Irs1 (Insulin
receptor substrate 1), a downstream mediator of the
growth factor/insulin signaling pathway that negatively
regulates gluconeogenesis [39] and Pklr  (Pyruvate
kinase), which encodes a glycolysis associated enzyme
known to catalyze the production of pyruvate from phos-
phoenolpyruvate [40].
The direction of regulation and the function of these
genes, suggests that in the liver of prednisolone-treated
WT, glucose metabolism is balanced towards gluconeo-
genesis, which is in line with the reported gluconeogenic
effect of glucocorticoids [41,42]. The reduced fold
changes in GRdim mice compared to WT mice (Table 2)
indicate that glucocorticoid-induced gluconeogenesis is
reduced in GRdim mice.
Cell cycle
Table 3 shows the prednisolone-regulated genes in WT
mice that CoPub identified as being associated with the
cell cycle. Upregulated genes include Gadd45b, Gadd45g
(Growth arrest and DNA-damage-inducible 45 beta and
gamma), Cdkn1a (Cyclin-dependent kinase inhibitor 1a;
also known as p21) and Plk3 (Polo-like kinase 3), which
are stress sensors involved in cell cycle arrest, DNA repair
and apoptosis [43-45]. Other upregulated genes are
Bcl2l1  (also known as Bcl2-like1  and  Bcl-xl), an anti-
apoptotic protein that is enhanced by binding to the
Gadd45 family [46,47], and Dusp1, a p53 target gene
involved in cell cycle regulation [48].
Amongst the downregulated genes are Ccnd2 (Cyclin
D2) and Cks2 (Cdc28 protein kinase regulatory subunit 2),
both involved in cell cycle progression [49,50]. Overall,
the direction of the prednisolone-induced differential
regulation of genes associated with the cell cycle suggests
that prednisolone induces a cytostatic response in liver of
WT mice.
Foxo transcription
From the literature-based network, the two transcription
factors Foxo1 and Foxo3a appear to be intermediates
between the gluconeogenesis and cell cycle and apoptosis
subnetworks (Figure 3). Foxo transcription factors are key
mediators of cell cycle progression, apoptosis, glucose
metabolism, reactive oxygen species detoxification and
DNA damage repair [51-54]. Their activity is tightly con-
trolled by the insulin and growth factor-inducible Pi3k/
Akt pathway. Akt-mediated phosphorylation of Foxo
transcription factors promotes their translocation from
the nucleus to the cytosol and thereby their inactivation
through binding of 14-3-3 proteins [54-56].
Foxo transcription factors regulate gene expression of
enzymes that are important regulators of gluconeogene-
sis, such as Pck1 and G6p [57,58]. In addition, they sup-
press genes that are involved in glycolysis, the pentose
shunt and lipogenesis [59]. Analysis of Foxo1-overex-
pressing mice revealed an increased expression of Igfbp1
Table 1: CoPub keyword enrichment analysis on 
prednisolone-regulated genes.
Biological process # of associated genes
Metabolism
Glucose metabolism/transport 22
Gluconeogenesis 21
Lipid metabolism/glycosylation 21
Glycolysis 14
Carbohydrate metabolism/
transport
14
Amino acid metabolism/transport 13
Cell cycle and apoptosis
Apoptosis 77
Cell proliferation 72
Cell cycle 65
Cell growth and-or maintenance, 
cell growth
63
Homeostasis 58
Cell differentiation 49
Cell cycle arrest 37
Immune/inflammatory response
Inflammatory response 31
Acute-phase response 20
CoPub was used to calculate keyword enrichment in the set of 
prednisolone-regulated probe sets in wild type mice. The 
analysis revealed that the differential regulated genes (non-
redundant set) are predominantly involved in three main 
processes: metabolism, cell cycle and apoptosis, and immune/
inflammatory response. The right column shows the number of 
differential regulated genes associated with a specific enriched 
keyword.Frijters et al. BMC Genomics 2010, 11:359
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(Insulin-like growth factor binding protein 1), Pck1, Tat
and Tdo  (Tryptophan 2,3-dioxygenase) and downregula-
tion of Srebf1 (Sterol regulatory element binding factor 1)
and Adipor2 (Adiponectin receptor 2) in liver [59]. Inter-
estingly, these genes are similarly regulated in predniso-
lone-treated WT mice (Figure 3 and Table 2).
Finally, Foxo transcription factors are regulators of cell
cycle progression and were shown to induce Cdkn1a and
Gadd45b  [60] and to suppress Ccnd2  [54]. Also these
genes show the same direction of regulation in predniso-
lone-treated WT mice (Figure 3 and Table 3). These
observations suggest that GCs in WT mice induce Foxo
transcription factors, which in turn may synergize with
the GR to modulate the expression of their respective tar-
get genes.
Prednisolone-induced differential gene expression in WT 
versus GRdim mice
Table 2 and 3 list a number of genes that are significantly
regulated by prednisolone in WT mice. In the GRdim mice
these genes do not meet the significance cutoff for differ-
ential regulation (p < 0.01), but for most of them a small
effect of prednisolone on the expression level can be
observed in GRdim  mice. To analyze these differences
quantitatively, we plotted the log2 ratios of gene expres-
sion after prednisolone treatment in WT versus GRdim
mice (Figure 4). This figure shows that on average, genes
in WT mice are more strongly regulated than in GRdim
mice after prednisolone treatment and confirms that
induction of gene expression by prednisolone is not abro-
gated in GRdim mice but reduced to on average 33% of the
Figure 3 Literature-based network of glucocorticoid-induced effects. A network representation of the enrichment results was generated, in 
which differentially expressed genes together with enriched keywords are plotted. Genes are shown as circles (Red: upregulated; Green: downregu-
lated), whereas enriched keywords are shown as squares. Connections between genes and keywords represent co-publications in Medline abstracts. 
To avoid an over-complex network, thresholds were set to simplify the interpretation of the results. Only keywords and genes that share at least 5 
publications and have an R-scaled score of at least 45 are plotted in the network [34]. Several higher-order biological processes that are affected by 
prednisolone can be appreciated: cell cycle and apoptosis, acute-phase response, stress response, amino acid metabolism, gluconeogenesis and lipid 
metabolism.Frijters et al. BMC Genomics 2010, 11:359
http://www.biomedcentral.com/1471-2164/11/359
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level in WT mice, as indicated by the slope of the dotted
line in Figure 4.
Identification of genes that differentially respond to 
prednisolone in GRdim mice as compared to WT mice
In Figure 4, several genes are highlighted that show a dif-
ferent response upon prednisolone treatment in WT
mice than in GRdim mice.
Unexpectedly, a small subset of these genes shows
stronger upregulation by prednisolone in GRdim  mice
compared to WT mice. These genes include Car8 (Car-
bonic anhydrase 8), a protein associated with prolifera-
tion and invasiveness of colon cancer cells [61], Zdhhc23
(Zinc finger, DHHC-type containing 23), a Nitric oxide
synthase-binding and activation protein [62], Flvcr2
(Feline leukemia virus subgroup C cellular receptor family,
member 2), a calcium-chelate transporter [63], and Amy2
(Amylase 2), an amylase that catalyzes the endohydrolysis
of 1,4-alpha-D-glucosidic linkages in oligosaccharides.
Genes that appear to strictly rely on GR dimerization
include  Dusp1,  Gadd45b,  Cdkn1a,  Foxo3a,  Plk3  and
Fam107a (Figure 4 and 5). As discussed above, Foxo3a,
Dusp1, Gadd45b, Cdkn1a and Plk3 all participate in cell
cycle regulation, apoptosis and DNA damage repair [43-
45,52]. The most striking difference in the level of regula-
tion by prednisolone between WT and GRdim mice was
observed for Fam107a  (also known as Tu3a  and Drr1)
(Figure 4, 5 and 6). The expression profile suggests that
transcription of Fam107a is under direct control of the
GR and strictly depends on its dimerization. Fam107a
encodes a ubiquitously expressed protein that was first
described in the context of renal cell carcinoma, in which
Fam107a expression is reduced or absent due to promo-
tor hypermethylation [64-66]. Overexpression of
Table 2: Prednisolone-regulated genes associated with 'gluconeogenesis' in literature.
Biological process: gluconeogenesis
Gene name Symbol Fc WT Fc GRdim*
Insulin-like growth factor binding protein 1 Igfbp1 9.7 3.6
Tyrosine aminotransferase Tat 4.1 1.6
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 Pfkfb3 3.9 2.3
Peroxisome proliferative activated receptor, gamma, coactivator 1 alpha Ppargc1a 3.2 3.2
CCAAT/enhancer binding protein (C/EBP), beta Cebpb 3.1 1.6
Protein-tyrosine sulfotransferase 2 Tpst2 2.7 1.5
Solute carrier family 2 (facilitated glucose transporter), member 1 Slc2a1 2.6 1.9
Forkhead box O1 Foxo1 2.2 1.7
Serine dehydratase Sds 2.1 1.5
Aminoadipate-semialdehyde synthase Aass 2.1 1.3
Phosphoenolpyruvate carboxykinase 1, cytosolic Pck1 1.9 1.3
Tryptophan 2,3-dioxygenase Tdo2 1.5 1.2
Aconitase 2, mitochondrial Aco2 1.4 1.3
Transketolase Tkt -1.2 -1.1
Protein kinase, AMP-activated, beta 1 non-catalytic subunit Prkab1 -1.5 1
Adiponectin receptor 2 Adipor2 -1.6 -1.3
Purinergic receptor P2Y, G-protein coupled, 5 P2ry5 -1.6 -1.3
Pyruvate kinase liver and red blood cell Pklr -2.1 -1.4
CCAAT/enhancer binding protein (C/EBP), alpha Cebpa -2.3 -1.2
Sterol regulatory element binding factor 1 Srebf1 -3 -1.6
Insulin receptor substrate 1 Irs1 -4 -1.5
CoPub identified 21 prednisolone-regulated genes in wild type (WT) mice that are associated in literature with gluconeogenesis. The 
identified genes share at least 3 publications and have an R-scaled score [34] of at least 35 with keyword 'gluconeogenesis' in Medline 
abstracts. For each gene, the fold change (Fc) in prednisolone versus vehicle-treated WT mice (Fc WT) is given. Additionally, for each gene 
also the Fc in prednisolone versus vehicle-treated GRdim mice (Fc GRdim) is shown. *It should be noted that in GRdim mice these genes did not 
meet the p-value cutoff of 0.01 for significance after correction for multiple testing, and are mentioned to illustrate a small effect of 
prednisolone on gene expression in GRdim mice.Frijters et al. BMC Genomics 2010, 11:359
http://www.biomedcentral.com/1471-2164/11/359
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Fam107a in Fam107a-negative cell lines leads to growth
retardation and apoptosis, indicating that Fam107a might
act as a tumor suppressor [65,67]
We also identified a subset of genes that showed an
equal induction of gene expression by prednisolone in
WT and GRdim mice (located on the diagonal black line in
Figure 4); Dst (Dystonin), a cytoskeletan-interacting pro-
tein postulated to cross-link cytoskeletal filaments and
thereby maintain cellular integrity [68], Gtf2a2 (General
transcription factor II A, 2), a subunit of the transcription
initiation factor TFIIA [69], Agpat6  (1-acylglycerol-3-
phosphate O-acyltransferase 6), an enzyme involved in
triglyceride synthesis [70], Marcks (Myristoylated alanine
rich protein kinase C substrate), cytoskeletal protein
involved in cell adhesion and cell motility [71], Obfc2a
(Oligonucleotide/oligosaccharide-binding fold containing
2A), a single stranded nucleic-acid-binding protein [72],
and Ppargc1a.
Prednisolone-induced changes in gene expression in
WT and GRdim  mice were validated by Q-PCR for
Fam107a, Dusp1, Cdkn1a and Car8. Figure 6 shows the
fold-changes of the selected genes in prednisolone versus
vehicle-treated WT and GRdim mice. For all four genes,
the regulation by prednisolone in WT and GRdim mice
was qualitatively similar to what was found by microarray
analysis.
Discussion and Conclusion
In this study we performed liver gene expression profiling
of WT and GRdim mice after prednisolone administration.
Our aim was to chart the biological processes in the liver
that are affected by GCs and to study their dependence
on DNA-binding and dimerization of the GR. CoPub
keyword enrichment analysis with prednisolone-regu-
lated genes in WT mice showed enrichment of keywords
associated with glucose, lipid and amino acid metabo-
lism, the cell cycle and apoptosis (Table 1 and Figure 3).
Table 3: Prednisolone-regulated genes associated with 'cell cycle' in literature.
Biological process: cell cycle
Gene name Symbol Fc WT Fc GRdim*
Growth arrest and DNA-damage-inducible 45 gamma Gadd45g 17.8 2.9
Dual specificity phosphatase 1 Dusp1 8.2 1
Cyclin-dependent kinase inhibitor 1A (P21) Cdkn1a 8.1 1
Growth arrest and DNA-damage-inducible 45 beta Gadd45b 5.1 1
Polo-like kinase 3 (Drosophila) Plk3 4.5 1
Retinoblastoma binding protein 8 Rbbp8 4.5 1.3
Bcl2-like 1 Bcl2l1 31 . 1
Tensin 1 Tns1 2.6 1.2
Protein tyrosine phosphatase 4a1 Ptp4a1 2.3 1.1
Forkhead box O1 Foxo1 2.2 1.7
PAX interacting (with transcription-activation domain) protein 1 Paxip1 1.9 1
Forkhead box O3a Foxo3a 1.9 -1.1
E1A binding protein p300 Ep300 1.8 1
NIMA (never in mitosis gene a)-related expressed kinase 7 Nek7 1.8 1.1
Cell division cycle 2-like 6 (CDK8-like) Cdc2l6 1.8 1.2
Cell division cycle 40 homolog (yeast) Cdc40 1.4 1
Cyclin D2 Ccnd2 -1.5 -1.2
NIMA (never in mitosis gene a)-related expressed kinase 6 Nek6 -1.7 -1.2
CDC28 protein kinase regulatory subunit 2 Cks2 -2.3 -1.3
TSC22 domain family, member 1 Tsc22d1 -4 -2.3
CoPub identified 65 prednisolone-regulated genes in wild type (WT) mice that are associated in literature with the cell cycle (top 20 shown). 
The identified genes share at least 3 publications and have an R-scaled score [34] of at least 35 with keyword 'cell cycle' in Medline abstracts. 
For each gene, the fold change (Fc) in prednisolone versus vehicle-treated WT mice (Fc WT) is given. Additionally, for each gene also the Fc 
in prednisolone versus vehicle-treated GRdim mice (Fc GRdim) is shown. *It should be noted that in GRdim mice these genes did not meet the p-
value cutoff of 0.01 for significance after correction for multiple testing, and are mentioned to illustrate a small effect of prednisolone on gene 
expression in GRdim mice.Frijters et al. BMC Genomics 2010, 11:359
http://www.biomedcentral.com/1471-2164/11/359
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This is in agreement with cellular processes known to be
affected by GCs [73,74]. Interestingly, the forkhead tran-
scription factors Foxo1 and Foxo3a are regulators of these
cellular processes and induced by prednisolone in WT
mice. Together with the observation that a subset of the
prednisolone-induced genes are Foxo1 and Foxo3a target
genes and are similarly regulated in Foxo1 and Foxo3a
expression profiling experiments [54,59,60], this suggests
that the GR synergizes with these transcription factors in
mouse liver to control lipid and glucose metabolism and
the cell cycle. This concept is further supported by the
recent finding that the MurF1  (M u s c l e  R I N G  fi n g e r  1 )
promoter contains adjacent binding sites for the GR and
Foxo transcription factors and is synergistically activated
when both are co-expressed [75]. However, it is likely that
a subset of the prednisolone-induced genes is under
direct control of Foxo1 and Foxo3a without the need for
synergy with the GR. Other studies, addressing small
gene sets or individual genes, had also identified a role for
Foxo1 and Foxo3a in GR-induced gene expression [58,75-
77].
The list of differentially regulated genes by predniso-
lone in WT mice overlaps with that of an earlier study by
Figure 4 Log2 ratio plot of prednisolone-induced differential 
gene expression in wild type versus GRdim mice. Genes on the solid 
black line show an equal induction of differential gene expression by 
prednisolone in wild type (WT) versus GRdim mice. The black-dotted 
line indicates the average slope of the data and shows that the level of 
gene regulation in prednisolone-treated GRdim mice is 33% of that ob-
served in WT mice. A subset of genes that show obvious differences in 
the magnitude of regulation by prednisolone in WT versus GRdim mice 
is highlighted, as well as genes that show equal magnitude of regula-
tion in WT versus GRdim mice.
Figure 5 Intensity profiles of Plk3, Dusp1, Gadd45b, Cdkn1a, 
Foxo3a and Fam107a in vehicle and prednisolone-treated wild 
type and GRdim mice. Several genes were identified that showed dif-
ferences between prednisolone-treatment in wild type (WT) and GRdim 
mice. Amongst those genes are Plk3, Dusp1, Gadd45b, Cdkn1a, Foxo3a 
and Fam107a were differential regulated in prednisolone-treated WT 
mice, but not in GRdim mice. White bars represent vehicle-treated mice, 
whereas grey bars represent prednisolone-treated mice. Symbols; Tri-
angles: female mice, Bullets: male mice.
Figure 6 Validation of microarray-obtained gene expression by 
Q-PCR. The relative expression of Fam107a, Dusp1, Cdkn1a and Car8 in 
prednisolone-treated versus vehicle-treated wild type (WT) and GRdim 
mice was validated by Q-PCR. Differences in expression between two 
samples were calculated by the 2ΔΔCt method [103,104]. Mean differ-
ences in gene expression between WT and GRdim mice were analyzed 
using the Student's t-test. No expression was observed for Fam107a 
and Cdkn1a in vehicle and prednisolone-treated GRdim mice (Ct > 30). 
Asterisks denote p-values as follows: *p < 0.05, **p < 0.01 and ***p < 
0.001.Frijters et al. BMC Genomics 2010, 11:359
http://www.biomedcentral.com/1471-2164/11/359
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Phuc Le et al, which combined chromatin immunopre-
cipitation (ChIP) data with gene expression data to iden-
tify direct GR target genes in mouse liver [78]. Most of
the genes found in our study displayed the same up and
downregulation of gene expression, such as Tat, Foxo1
and Fkbp5 that are upregulated and Adipor2, CCAAT/
enhancer binding protein alpha (C/EBPα) and Tkt that are
downregulated. From a candidate gene set of 302 genes,
Phuc Le et al identified metabolism, cell proliferation and
programmed cell death as important processes in their
GO-term analysis, which is in agreement with our find-
ings.
Interestingly, in contrast to our study, Phuc Le et al did
not observe upregulation of bona fide GR target genes,
such as Pck and Igfpb in fed CD1 mice and explain this by
lack of response due to a potential inhibition by insulin
signaling in the fed state [79]. The fact that we observed
upregulation of these genes indicates that in our experi-
mental setup, which differs in several aspects from the
setup used by Phuc Le et al, such as mouse strain used for
the study, GC dosage and the fed state of the mice, the
inhibitory effects of fed-induced insulin signaling do not
play a role.
The overall induction of gene expression was strongly
reduced in prednisolone-treated GRdim mice compared to
WT mice (Figure 4). Nevertheless, in many cases residual
gene induction by prednisolone was still observed. This
indicates that GR dimerization is indeed an important
mechanism for activation of these genes, although some
regulation can take place even in the absence of GR
homodimers. In fact, GR monomers are in principle
capable of binding to GC response elements (GREs) and
evoking a basal induction of gene expression. However,
due to the lack of cooperative binding they are less potent
than GR homodimers. This is in line with the regulation
reported for Pnmt (Phenylethanolamine-N-methyltrans-
ferase) and Amy2 in which binding of GR monomers to
GREs or a GRE half-site (i.e. only one-half of the classical
palindrome) was sufficient to confer induction by GCs
[80,81]. In case of the Pnmt gene, multiple GRE half-site
have been identified in the promoter region allowing
receptor clustering and thereby stable binding of GR
monomers independent of the DNA-binding domain
(DBD) interface [80]. This also explains why expression of
the Pnmt gene is not compromised in GRdim mice despite
the lack of GR dimer formation [21]. Another explanation
for the residual gene induction by prednisolone in GRdim
mice is that the mutant GR still forms homodimers but
that these are far less stable than in WT mice.
A recent study showed that the specific sequence of a
GRE differently affects the conformation of the GR and
thereby its activity towards specific target genes [82].
Mutation analysis of overexpressed GR domains that are
involved in transcriptional activation, namely the
dimerization region in the DBD (Dim) as well as AF1 and
AF2 (activation function 1 and 2), showed that the depen-
dency on each of them was specific for the sequence of
the GR binding site and that genes differed in their
dependence on dimerization [82]. The fold induction of
Tat and Fkbp5 by dexamethasone in the Dim mutant was
around 30% for Tat  and 50% for Fkbp5 of that for WT
GR, which is in gross agreement with our own observa-
tions in vivo (Figure 4).
The effect of the GRdim mutation was found in all major
pathways that were induced by prednisolone, i.e. for
genes in inflammatory pathways, gluconeogenesis and
cell cycle. Moreover, the attenuating effect of the GRdim
mutation was found for genes that were upregulated as
well as for genes that were downregulated by predniso-
lone. This suggests that genes, which fail to be repressed
by prednisolone in GRdim  mice, are either regulated
through GR binding to negative GRE elements (nGREs)
or indirectly regulated via other GR target genes. Inter-
estingly, analysis of the magnitude of gene regulation by
prednisolone in WT mice compared to GRdim  mice
showed that the cell cycle-related genes are more depen-
dent on the dim interface than genes related to gluconeo-
genesis (Table 2 and 3). This can also be appreciated in
Figure 4; several genes that are on the x-axis (i.e. show no
differential gene expression upon prednisolone treatment
in GRdim mice), are cell cycle-related.
We identified several genes that showed strong upregu-
lation by prednisolone in GRdim mice compared to WT
mice, such as Amy2,  Car8  and  Zdhhc23, and several
genes that showed equal induction of gene expression by
prednisolone in WT and GRdim mice, amongst them are
Dst and Ppargc1a (Figure 4). These genes are potential
candidates for having GRE half-sites in their promotor
regions, which could explain why these genes show equal
or even higher induction of gene expression by predniso-
lone compared to WT mice. As mentioned earlier , the
presence of GR half-sites in the promotor region for
Amy2 was indeed experimentally confirmed [81]. For the
other genes however, we did not find literature evidence
for the presence of GR half-sites in their promotor
regions. Therefore, follow-up studies on these genes to
determine the functional GRE sites in their regulatory
region would be of interest to study the significance of
dimer-interface independent GRE binding. Genes that
showed equal or stronger upregulation by prednisolone
in GRdim mice compared to WT mice can also be second-
ary response genes; under transcriptional control of tran-
scription factors other than the GR. Keyword enrichment
analysis performed with this set of genes did not identify
enrichment for a particular cellular process.
We identified several genes that are absolutely depen-
dent on GR dimerization for the induction of geneFrijters et al. BMC Genomics 2010, 11:359
http://www.biomedcentral.com/1471-2164/11/359
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expression by prednisolone, such as Cdkn1a, Gadd45b,
Dusp1, Plk3 and Foxo3a  (Figure 4). Interestingly, all of
these have a strong relationship with p53: some are under
direct transcriptional control of p53 (Cdkn1a  [83],
Gadd45b [84] and Dusp1 [48]) or physically interact with
p53 (Foxo3a [85,86] and Plk3 [87]). The cellular responses
mediated by Foxo3a and p53 are highly similar, share
some of their target genes (e.g. Cdkn1a and Gadd45b)
and use similar mechanisms to regulate post-transla-
tional modification [51,88]. Therefore, Foxo3a and p53
can be regarded as partners that positively as well as neg-
atively regulate each other, depending on the context [51].
This observation might indicate that GC-induced activa-
tion of Foxo3a and/or p53 is hampered in GRdim mice. In
line with this hypothesis Foxo3a was recently shown to be
required for GC-induced apoptosis in lymphocytes [89].
Interestingly, this process is defective in GRdim mice high-
lighting a possible link between the GR, Foxo3a and
induction of lymphocyte apoptosis [21].
Fam107a showed the largest induction of gene expres-
sion by prednisolone in WT mice (Figure 4 and 5). Analy-
sis of protein-protein interactions revealed that Fam107a
interacts with Tada2a [90,91], a protein that together with
binding partner Tada3a (Transcriptional adaptor 2 and 3
alpha) are core proteins of the histone acetyltransferase
(HAT) complex [92]. HAT complexes are involved in
chromatin structure modification for initiation of gene
transcription, but can also acetylate non-histone proteins
to modify their activity and stability [92,93]. Interestingly,
Fam107b a paralog of Fam107a with 84% protein similar-
ity (not regulated in mouse liver by prednisolone) was
shown to interact with Tada3a [94].
The observation that Fam107a inhibits cell prolifera-
tion and induces apoptosis when overexpressed [65,67],
suggests that Fam107a, like Foxo3a, Dusp1, Gadd45b,
Cdkn1a and Plk3 play a role in regulating the cell cycle.
Furthermore, the association of Fam107a with a core pro-
tein of the HAT complex might indicate that Fam107a
may serve as a cofactor in the transcription machinery
complex.
The activity and function of Foxo3a and p53 are
strongly modulated by acetylation [51,88,95]. Hence,
Fam107a is an interesting candidate gene for follow up
experiments to study whether it modulates GR-induced
gene expression and/or acetylation of GR-associated
transcription factors such as Foxo3a, p53, C/EBPα and C/
EBPβ (CCAAT/enhancer binding protein, beta).
For a more comprehensive view on GC regulated pro-
cess in the liver, experiments with multiple time points,
different doses of GCs and using one or more inflamma-
tory stimuli, could be considered.
Methods
Animals
All mice (WT and GRdim; Balb/c) were bred at the Insti-
tute of Virology and Immunobiology at the University of
Würzburg. In total 24 mice (8 male WT, 4 female WT, 8
male GRdim and 4 female GRdim) were included in the
study. Mice were treated subcutaneously with 1 mg/kg
prednisolone (5% DMSO and 5% Chremophor in mani-
tol, 10 ml/kg) once and sacrificed 150 minutes later by
cervical dislocation, which was approved by the responsi-
ble authorities in Bavaria (Regierung von Unterfranken).
All experiments were performed in the morning between
9 and 10 AM. The mice were exposed to a regular dark-
light-cycle (lights on between 6 AM and 6 PM) and had
access to water and food ad libitum at any time.
RNA isolation
Liver biopsy specimens were collected into aluminum
containers, snap freezed in liqN2 and stored at -80°C
before use. RNA isolation was done using Trizol, followed
by RNeasy clean-up to enhance the A260/A230 ratio. RNA
quantity and quality was determined using the NanoDrop
Spectrophotometer and Agilent Bioanalyzer. For all sam-
ples subjected to microarray hybridization, the RIN
(RNA integrity number) was 9.0 - 10.
Microarray data processing
Processed RNA samples were hybridized on GeneChip
Mouse Genome 430 2.0 arrays (MOE430-2) from
Affymetrix [96]. Processing and downstream statistical
analysis of the microarray data was done using the R Sta-
tistics package [97]. Data were normalized using the
gcrma algorithm, pair-wise ratios between treatments
were built using the limma package and annotation for
the probe sets was derived from the mouse4302 library,
all as provided in BioConductor [98]. In all contrast
matrices, a correction for gender type was applied. Data
were deposited in the NCBI Gene Expression Omnibus
(GEO), accession number GSE21048.
Keyword enrichment analysis
Keyword enrichment analysis on the microarray data was
performed using CoPub [34] with default settings as pro-
vided by the web server [99]. The literature-network
between enriched keywords and genes (nodes) and their
co-publications (edges) were visualized using Cytoscape
software [100,101].
Validation of microarray results with Q-PCR
Total RNA (1 μg) was reverse transcribed using a com-
mercially available cDNA synthesis kit (iScript, BioRad
Laboratories, Hercules, CA, USA). Q-PCR was per-
formed by SYBR Green-based quantification according toFrijters et al. BMC Genomics 2010, 11:359
http://www.biomedcentral.com/1471-2164/11/359
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the manufacturer's protocol (Applied Biosystems, Foster
City, CA, USA). Primers were developed for Fam107a
(Family with sequence similarity 107, member a;
Fw:TCATCAAACCCAAGAAGCTG; Rev: CTCAG-
GCTTGCTGTCCATAC), Car8 (Carbonic anhydrase 8;
Fw: CACACCATTCAAGTCATCCTG; Rev: ACCA-
CGCTGGTTTTCTCTTC), Cdkn1a (Cyclin-dependent
kinase inhibitor 1a; Fw: TCTTGCACTCTGGTGTCT-
GAG; Rev: ATCTGCGCTTGGAGTGATAG) and Dusp1
(Dual specificity phosphatase 1; Fw: GTGCCTGACAGT-
GCAGAATC; Rev: CCAGGTACAGGAAGGACAGG)
using Primer3 [102]. All primer pairs were exon-span-
ning. The gene Azgp1 (alpha-2-glycoprotein 1, zinc-bind-
ing; Fw: AAGGAAAGCCAGCTTCAGAG; Rev:
ACCAAACATTCCCTGAAAGG) was chosen as endog-
enous control since the expression arrays did not show
any differences in expression of this gene between the
two experimental groups (WT vs GRdim). PCR products
were selected to be between 80 and 120 bp long. Samples
were run on the 7500 Fast Real-Time PCR System
(Applied Biosystems) using the following protocol: 10
min. denaturation at 95°C, and 40 cycles of 15 sec. dena-
turation at 95°C, 60 sec. annealing and extension at 60°C.
All primer pairs were validated in triplicate using serial
cDNA dilutions. Primer pairs that were 100 ± 10% effi-
cient, which implies a doubling of PCR product in each
c y c l e ,  w e r e  u s e d  t o  q u a n t i f y  m R N A  l e v e l s .  T h r e s h o l d
cycle numbers (referred to as Ct) were obtained using the
7900 HT System SDS software version 2.3 (Applied Bio-
systems). All samples were measured for three times and
samples with a standard deviation (SD) larger than 0.5
were excluded from the analysis. The relative quantity
(RQ) of the gene-specific mRNA was calculated from the
average value of the ΔCt (target gene Ct - endogenous
control gene Ct) for each of the 24 analyzed samples. Dif-
ferences in expression between two samples were calcu-
lated by the 2ΔΔCt method [103,104]. For Q-PCR, mean
differences in expression between groups were analyzed
using the Student's t-test. A p-value of < 0.05 was consid-
ered statistically significant in each situation.
Protein - protein interaction data
Protein-protein interaction data were retrieved from the
Biological General Repository for Interaction Datasets
(BioGRID) database [105,106].
Additional material
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